Trial Profile
A Phase 1/2a Dose Escalation and Cohort Expansion Study for Safety, Tolerability, and Efficacy of BMS-986156 Administered Alone and in Combination With Nivolumab (BMS-936558, Anti PD-1 Monoclonal Antibody) in Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Mar 2023
Price :
$35
*
At a glance
- Drugs BMS 986156 (Primary) ; Nivolumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Bristol-Myers Squibb
- 15 Dec 2020 Status changed from active, no longer recruiting to completed.
- 15 Jun 2020 This trial is completed in Netherland (Global End Date: 16 Dec 2019), according to European Clinical Trials Database record.
- 08 Feb 2020 This trial has been completed in Germany, according to European Clinical Trials Database record.